a study of jnj-73763989, pegylated interferon alpha-2a, nucleos(t)ide analog (na) with or without jnj-56136379 in treatment-naive participants with hepatitis b e antigen (hbeag) positive chronic hepatitis b virus (hbv) infection

Conditions: Hepatitis B, Chronic

Summary: the purpose of this study is to evaluate the efficacy of a treatment regimen of jnj-73763989 + pegylated interferon alpha-2a (pegifn-alpha-2a) + nucleos(t)ide analog (na).

hepatitis b virus (hbv) is a small deoxyribonucleic acid virus that specifically infects the human liver. the acute phase of infection is either followed by an immune controlled state or progresses to chronic hepatitis b. the worldwide estimated prevalence of chronic hbv infection is about 292 million people affected. hepatitis b surface antigen (hbsag) seroclearance is currently considered to be associated with the most thorough suppression of hbv replication (termed functional cure). with current available na treatment strategies, rate of hbsag seroclearance remains very low (around 3 percent \[%\]) even under long-term treatment. also, with the persistently high global prevalence of hbv-associated mortality, there is a medical need for more effective finite treatment options that lead to sustained hbsag seroclearance. jnj-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic hbv infection via a ribonucleic acid interference (rnai) mechanism. jnj-56136379 is an orally administered capsid assembly modulator (cam) that is being developed for the treatment of chronic hbv infection. the aim of the study is to evaluate the efficacy of a treatment regimen of jnj-73763989 + pegifn-alpha-2a + na with or without jnj-56136379 in participants with hepatitis b e antigen (hbeag) positive chronic infection. the study will be conducted in 4 phases: a screening phase, an induction phase with flexible duration, a consolidation phase with or without pegifn-α2a and a follow-up phase. safety assessments will include adverse events (aes), serious aes of the study interventions, clinical laboratory tests, electrocardiograms (ecgs), vital signs, and physical examinations. the study title reflects the original study design and jnj-56136379 (jnj-6379) was initially part of the study intervention but was discontinued as per amendment 6 of the study.

Eligibility criteria:
inclusion criteria: * medically stable based on physical examination, medical history, vital signs, laboratory values, and 12-lead electrocardiogram (ecg) at screening * currently not treated chronic hepatitis b virus (hbv) infection with alanine transaminase (alt) less than (\ =) 20,000 international units per milliliter (iu/ml) * body mass index (bmi) between 18.0 and 35.0 kilogram per meter square (kg/m\^2), extremes included * liver fibrosis stage 0-2 (metavir) or fibroscan less than or equal to (\<=) 9 kilopascal (kpa) at screening exclusion criteria: * evidence of infection with hepatitis a, c, d or e virus infection or evidence of human immunodeficiency, virus type 1 (hiv-1) or hiv-2 infection at screening * history or evidence of clinical signs or symptoms of hepatic decompensation, including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices * evidence of liver disease of non-hbv etiology * participants with a history of malignancy within 5 years before screening * participants who had or planned major surgery, (example, requiring general anesthesia) or who have received an organ transplant * contraindications to the use of pegifn-α2a